Implantable Cardioverter-Defibrillators are the Main Link in the Modern Concept of Sudden Cardiac Death Prevention. Problems and Prospects of the Development of the Method
https://doi.org/10.18087/cardio.2018.12.10197
Abstract
The article covers the development of the problem of sudden cardiac death prevention with the implantable cardioverterdefibrillators from the moment of creation of these devices to our days. The current concept of primary prevention of sudden cardiac death, based on the severity of manifestation of heart failure and left ventricular dysfunction, is not effective enough. Its practical application is difficult because it requires mass application of implantable defibrillators, with low predictive accuracy of these criteria in terms of development of lifethreatening arrhythmias. The development of methods for visualizing the myocardium, allowing to assess the severity of myocardial fibrosis, as well as the possibilities of medical genetics, at the present stage, allows us to clarify indications for implantation of cardioverterdefibrillators and thereby significantly improve the concept of preventing sudden cardiac death with these instruments.
About the Authors
L. A. Bokeria
Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Moscow
N. M. Neminushchiy
Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
Neminushchiy Nikolay M. - MD, professor.
Moscow
A. S. Postol
Federal centers of High Medical Technologies Health Ministry
Russian Federation
Russian Federation
Kaliningrad
References
1. Go A. S., Mozaffarian D., Roger V. L. et al. Heart Disease and Stroke Statistics - 2013 Update A Report From the American Heart Association. Circulation 2013;127: el - e240. DOI: 10.1161/CIR.0b013e31828124ad.
2. Deo R., Albert C. M. Epidemiology and Genetics of Sudden Cardiac Death. Circulation 2012;125 (4):620-637. DOI: 10.1161/CIRCULATIONAHA.111.023838.
3. Bokeria L. A., Revishvili A. Sh., Neminushchiy N. M. et al. Sudden Cardiac Death. Moscow: GEOTAR-Media 2011;272s. Russian
4. Zheng Z.J., Croft J. B., Giles W. H. et al. Sudden cardiac death in the United States, 1989 to 1998. Circulation 2001;104:2158-2163.
5. Chugh S. S., Jui J., Gunson K. et al. Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U. S. community. J Am Coll Cardiol 2004;44:1268-1275.
6. Krahn A. D., Connolly S. J, Roberts R. S. et al. Diminishing proportional risk of sudden death with advancing age: Implications for prevention of sudden death. Am Heart J 2004;147:837-840.
7. Luu M., Stevenson W. G., Stevenson L. W. et al. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation 1989;80:1675-1680.
8. Bayes de Luna A., Coumel P., Leclerq J. F. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am Heart J 1989;117:151-159.
9. Yang K.-C., Kyle J. W., Makielski J. C. et al. Mechanisms of Sudden Cardiac Death: Oxidants and Metabolism. Circ Res 2015;116:1937-1955. DOI: 10.1161/CIRCRESAHA.116.304691.
10. Gurvich N. L. Cardiac fibrillation and defibrillation. Moscow: Medgiz. 1957;250s. Russian (Гурвич Н. Л. Фибрилляция и дефибрилляция сердца. М: Медгиз. 1957;250 с).
11. Monsieurs K. G., Nolan J. P., Bossaert L. L. et al. European Resuscitation Council Guidelines for Resuscitation 2015 Section 1. Executive summary. Resuscitation 2015;95:1-80. DOI: 10.1016/j.resuscitation.2015.07.038
12. Gurvich N. L., Makarychev V. A. Defibrillation of heart by a two-phase electric pulse. Kardiologia 1967;7:109-112. Russian
13. Gurvich N. L., Tabak V.Ja., Bogushevich M. S. et al. Defibrillation of the heart by a two-phase impulse in an experiment and clinic. Kardiologia 1971;8:126-130. Russian
14. Negovskij V. A. Instruction on the application of methods for restoring vital functions of patients in terminal states. Moscow: Medgiz. 1959;50 s. Russian
15. Mirowski M., Reid P. R., Mower M. M. et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med 1980;303:322.
16. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators: A comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-1584.
17. Connolly S.J., Gent M., Roberts R. S. et al.: Canadian Implantable Defibrillator Study (CIDS): A randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000;101:1297-1302.
18. Kuck K. H., Cappato R., Siebels J., Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: The Cardiac Arrest Study Hamburg (CASH). Circulation 2000;102:748-754.
19. Moss A.J., Hall W.J., Cannom D. S. et al.: Improved survival with an implantable defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N EnglJ Med 1996;335:1933-1940.
20. Buxton A. E., Lee K. L., Fisher J. D. et al.: A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999;341:1882-1890.
21. Moss A.J., Zareba W., Hall W.J. et al. The Multicenter Automatic Defibrillator Implantation Trial II Investigators: Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-883.
22. Bardy G. H., Lee K. L., Mark D. B. et al. The Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators: Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-237.
23. Priori S. G., Blomstrom-Lundqvist C., Mazzanti A. et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J 2015;36 (41):2793-2867.
24. Revishvili A. Sh., Bojtsov S. A., Davtjan K. V. et al. Clinical Guidelines for electrophysiological studies, catheter ablation and use of implantable antiarrhythmic devices. 3rd ed. Moscow: MAKS Press, 2017. 701 s. Russian
25. Al-Khatib S. M., Stevenson W. G. Ackerman M.J. et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. J Am Coll Cardiol 2017; DOI: 10.1016/j.jacc.2017.10.053. http://www.onlinejacc.org/content/early/2017/10/19/j.jacc.2017.10.053
26. Revishvili A. Sh., Neminushchiy N. M., Golicyn S. P. et al. AllRussian Clinical Guidelines for the control of the risk of sudden cardiac arrest and sudden cardiac death, prevention and first aid. Moscow: GEOTAR-Media. 2018;256 s. Russian
27. Fomin I. V. Chronic heart failure in the Russian Federation: what do we know today and what should we do? Russian Cardiological Journal 2016; (8):7-13. DOI:10.15829/1560-4071-2016-8-7-13. Russian
28. Belenkov Ju. N., Fomin I. V., Mareev V. Ju. et al. The prevalence of chronic heart failure in the European part of the Russian Federation is the data of EPOCHA-CHF (part 2). Heart Fail J 2006; 7 (3):3-7. Russian
29. Kaiser D., Tsai V., Heidenreich P. A. et al. Defibrillator implantations for primary prevention in the United States: Inappropriate care or inadequate documentation: Insights from the National Cardiovascular Data ICD Registry. Heart Rhythm 2015;12:2086-2093. doi.org/10.1016/j.hrthm.2015.05.010
30. Hindricks G., Camm J., Merkely B. et al. The EHRA. White Book 2017. The Current Status of Cardiac Electrophysiology in ESC Member Countries. 2017; www.escardio.org/EHiRA.
31. Sabbag A., Suleiman M., Laish-Farkash A. et al. Contemporary rates of appropriate shock therapy in patients who receive implantable device therapy in a real-world setting: From the Israeli ICD Registry. Heart Rhythm 2015;12:2426-2433. DOI: 10.1016/j.hrthm.2015.08.020.
32. Merchant F. M., Jones P., Wehrenberg S. et al. Incidence of Defibrillator Shocks After Elective Generator Exchange Following Uneventful First Battery Life. J Am Heart Assoc 2014;3: e001289. DOI: 10.1161/JAHA.114.001289.
33. Erkapic D., Sperzel J., Stiller S. et al. Long-term benefit of implantable cardioverter/defibrillator therapy after elective device replacement : results of the INcidence free SUrvival after ICD REplacement (INSURE) trial - a prospective multicentre study. Eur Heart J 2013;34 (2):130-137. DOI: 10.1093/eurheartj/ehs177.
34. Jellis C., Martin J., Narula J., Marwick T. H. Assessment of nonischemic myocardial fibrosis. J Am Coll Cardiol 2010;56 (2):89-97. DOI: 10.1016/j.jacc.2010.02.047.
35. Nguyen T. P., Qu. Z., Weiss J. N. Cardiac fibrosis and arrhythmo-genesis: the road to repair is paved with perils. J Mol Cell Cardiol 2014;70:83-91. DOI: 10.1016/j.yjmcc.2013.10.018.
36. Morita N., Mandel W.J., Kobayashi Y., Karagueuzian H. S. Cardiac fibrosis as a determinant ofventricular tachyarrhythmias.J Arrhythm 2014; 30 (6):389-394. DOI:10.1016/j.joa.2013.12.008.
37. de Jong S., van Veen T. A., van Rijen H. V., de Bakker J. M. Fibrosis and cardiac arrhythmias. J Cardiovasc Pharmacol 2011;57:630-638. DOI: 10.1097/FJC.0b013e318207a35f.
38. Disertori M., Mase M., Ravelli F. Myocardial fibrosis predicts ventricular tachyarrhythmias. Trends in Cardiovasc Med 2017;27 (5):363-372. doi.org/10.1016/j.tcm.2017.01.011.
39. de Bakker J. M., van Capelle F.J., Janse M.J. et al. Slow conduction in the infarcted human heart. Zigzag course of activation. Circulation 1993;88 (3):915-926.
40. Green J. J., Berger J. S., Kramer C. M., Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. J Am Coll Cardiol Img 2012;5:370-377.
41. Kuruvilla S., Adenaw N., Katwal A. B. et al. Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis. Circ Cardiovasc Imaging 2014;7:250-258. DOI:10.1161/CIRCIMAGING.113.001144.
42. Di Marco A., Anguerra I., Schmitt M. et al. Late gadolinium enhancement and the risk of ventricular arrhythmias or sudden death in dilated cardiomyopathy: systematic review and meta-analysis. J Am Coll Cardiol HF 2017;5:28-38. oi.org/10.1016/j.jchf.2016.09.017
43. Disertori M., Rigoni M., Pace N. et al. Myocardial fibrosis assessment by LGE is a powerful predictor of ventricular tachyarrhythmias in ischemic and nonischemic LV dysfunction. J Am Coll Cardiol Img 2016;9:1046-1055. doi.org/10.1016/j.jcmg.2016.01.033.
44. Weng Z., Yao J., Chan R. H. et al. Prognostic value of LGE-CMR in HCM. A meta-analysis. J Am Coll Cardiol Img 2016;9:1392-1402. doi.org/10.1016/j.jcmg.2016.02.031.
45. Pinto Y., Elliott P. M., Arbustini E. et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J 2016;3:1850-1858. DOI:10.1093/eur-heartj/ehv727.
46. Arbustini E., Disertori M., Narula J. Primary Prevention of Sudden Arrhythmic Death in Dilated Cardiomyopathy. Current Guidelines and Risk Stratification. J Am Coll Cardiol Heart Failure 2017;5 (1) :39-42.doi.org/10.1016/j.jchf.2016.11.009.
47. Kober L., Thune J.J., Nielsen J. C. et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. Danish Study to Assess the Efficacy of ICDs in Patients with Non-ischemic Systolic Heart Failure on Mortality (DANISH). N Engl J Med 2016;375:1221-1230.
48. Bezzina C. R., Lahrouchi N., Priori S. G. et al. Genetics of Sudden Cardiac Death. Circ Res 2015;116:1919-1936. DOI: 10.1161/CIRCRESAHA.116.304030.
49. Dekker L. R. C., Bezzina C. R., Henriques J. P. S. et al. Familial Sudden Death Is an Important Risk Factor for Primary Ventricular Fibrillation. A Case-Control Study in Acute Myocardial Infarction Patients. Circulation 2006;114:1140-1145.
50. Bezzina C. R., Pazoki R., Bardai A. et al. Genome - wide association study identifies a susceptibility locus at 21q21 for ventricular fibrillation in acute myocardial infarction. Nat Genet 2010;42:688-691.
51. Arking D. E., Junttila M.J., Goyette P. et al. Identification of a sudden cardiac death susceptibility locus at 2q24.2 through genome -wide association in European ancestry individuals. PLoS Genet. 2011;7 (6):e1002158. DOI: 10.1371/journal.pgen.1002158.
52. Marsman R. F., Tan H. L., Bezzina C. R. Genetics of sudden cardiac death caused by ventricular arrhythmias. Nat Rev Cardiol 2014;11 (2) :96-111. DOI: 10.1038/nrcardio.2013.186.
53. Mellor G., Laksman Z. W. M., Tadros R. et al. Genetic Testing in the Evaluation of Unexplained Cardiac Arrest From the CASPER (Cardiac Arrest Survivors With Preserved Ejection Fraction Registry). Circ Cardiovasc Genet 2017;10: e001686. DOI: 10.1161/CIRCGENETICS.116.001686.
Review
For citations:
Bokeria L.A., Neminushchiy N.M., Postol A.S. Implantable Cardioverter-Defibrillators are the Main Link in the Modern Concept of Sudden Cardiac Death Prevention. Problems and Prospects of the Development of the Method. Kardiologiia. 2018;58(12):76-84. (In Russ.) https://doi.org/10.18087/cardio.2018.12.10197
Views:
2915
Email this article 
Post a Comment 
